Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab

You may be eligible if

• Histologically confirmed colorectal adenocarcinoma;
• Measurable metastatic disease according to RECIST criteria;
• Patients receiving BV plus FOLFIRI as first-line treatment;
• Written informed consent;
• Availability of blood samples for genetic analysis.-